https://piumedicina.it/salute-approvazione-aifa-per-il-rimborso-di-dapagliflozin-nel-trattamento-dello-scompenso-cardiaco/
Aifa approva il rimborso di dapagliflozin per il trattamento dello scompenso cardiaco, migliorando le opzioni terapeutiche per i pazienti.
saluteaifaperildi
https://www.ajmc.com/view/fda-grants-priority-review-to-dapagliflozin-for-ckd
The FDA decision on dapaglifozin for CKD is expected in the second quarter of 2021.
priority reviewfdagrantsdapagliflozinckd
https://mdexam.com/post/dapagliflozin-overview-does-it-work-for-weight-loss
Dapagliflozin, primarily used for type 2 diabetes, can potentially aid weight loss by inhibiting kidney glucose reabsorption, albeit with side effects...
does itweight lossdapagliflozinoverviewwork
https://www.acc.org/latest-in-cardiology/articles/2025/08/26/11/47/sat-215am-dapa-act-esc-2025
dapaacthftimipatients
https://astrazeneca.trialsummaries.com/Study/StudyDetails?uniqueStudyId=D9090C00007&tenant=MT_MED_9011
A phase Ib study of AZD5462 on top of dapagliflozin in participants with heart failure and moderate renal impairment
phase ibon topcomstudy
https://www.ajmc.com/view/dapa-ckd-dapagliflozin-drops-risk-of-renal-decline-or-kidney-failure-death-39-even-without
Results from the second major renal outcomes trial for an SGLT2 inhibitor affirm the role of the class in preventing renal decline and kidney failure.
dapackddropsriskrenal
https://www.sigmaaldrich.com/US/en/tech-docs/paper/1066261
SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy. by Paola Cassis, Monica Locatelli, Domenico Cerullo, Daniela...
inhibitordapagliflozinlimitspodocytedamage